JUBLIA—Cure rates with long-term treatment1
- JUBLIA achieved treatment success in 57% of cases over 72 weeks1
- JUBLIA achieved complete cure in 31% of cases over 72 weeks1
- JUBLIA achieved mycological cure in 62% of cases over 72 weeks1
In a multicenter, open-label, single-arm study, patients with moderate (>20% and ≤50% clinical involvement) and severe (>50% clinical involvement) onychomycosis were treated with efinaconazole 10% solution for more than 1 year.1
Debridement was not performed in this study.1
JUBLIA® (efinaconazole) topical solution, 10%, is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Important Safety Information
- JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
- Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
- The most common adverse reactions (incidence ≥1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
- JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients below 6 years of age have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact Ortho Dermatologics at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Click here for full Prescribing Information.
References: 1. Iozumi K, Abe M, Ito Y, et al. Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: a multicenter, single-arm study. J Dermatol. 2019;46(8):641-651.